share_log

Leerink Partners Initiates Coverage On Larimar Therapeutics With Outperform Rating, Announces Price Target of $25

Leerink Partners Initiates Coverage On Larimar Therapeutics With Outperform Rating, Announces Price Target of $25

Leerink Partners以跑贏大盤的評級啓動對Larimar Therapeutics的報道,宣佈目標股價爲25美元
Moomoo 24/7 ·  04/03 09:18

Leerink Partners analyst Joori Park initiates coverage on Larimar Therapeutics (NASDAQ:LRMR) with a Outperform rating and announces Price Target of $25.

Leerink Partners分析師Joori Park以跑贏大盤的評級啓動了對Larimar Therapeutics(納斯達克股票代碼:LRMR)的報道,並宣佈目標股價爲25美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論